Related Experiment Video
Updated: Jul 4, 2026

Quantitative Microtubule Fractionation Technique to Separate Stable Microtubules, Labile Microtubules, and Free Tubulin in Mouse Tissues
Published on: November 17, 2023
Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management
Sandra M Swain1, Joseph C Arezzo
1Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA. sandra.m.swain@medstar.net
Abstract:
Microtubule inhibitor (MTI)-based chemotherapies used in the treatment of breast cancer--including vinca alkaloids, taxanes, and epothilones--are known to be associated with peripheral neuropathy. The incidence and severity of neuropathy, most frequently sensory in nature, depend on the agent used, absolute and cumulative drug dose, administration schedule, and presence of comorbidities. Although some first-generation vinca alkaloids, such as vincristine, were associated with severe mixed sensory/motor neuropathy, the deficits associated with newer agents in this class (eg, vinflunine) are generally milder and limited to distal sensory signs and symptoms. Among the taxanes, sensory neuropathy is reported more often with administration of paclitaxel and albumin-bound paclitaxel and less frequently with docetaxel. Epothilones, a new class of MTI, may be associated with grade 3/4 peripheral neuropathy; however, the neuropathy associated with ixabepilone, a novel epothilone B analog, is generally mild to moderate and reversible to baseline or grade 1 levels. The neuropathy induced by MTI therapy is best managed with dose adjustments and/or treatment delay. This article provides an overview of the incidence, characteristics, and management of MTI-associated neurotoxicities for known vinca alkaloids and taxanes, as well as newer agents, such as vinflunine and ixabepilone.
Insights
Microtubule inhibitor chemotherapies for breast cancer can cause peripheral neuropathy. Newer agents and dose adjustments may reduce neurotoxicity risks and improve patient outcomes.
Area of Science:
- Oncology
- Neuroscience
- Pharmacology
Background:
- Microtubule inhibitors (MTIs) like vinca alkaloids, taxanes, and epothilones are crucial in breast cancer treatment.
- These therapies are frequently linked to chemotherapy-induced peripheral neuropathy (CIPN).
- CIPN incidence and severity vary based on the specific MTI, dosage, schedule, and patient factors.
Purpose of the Study:
- To review the incidence, characteristics, and management of MTI-associated neurotoxicities.
- To compare neuropathy profiles of older versus newer MTIs in breast cancer therapy.
- To provide insights into managing MTI-induced peripheral neuropathy.
Main Methods:
- Literature review of MTI-based chemotherapies for breast cancer.
- Analysis of reported peripheral neuropathy incidence and characteristics for vinca alkaloids, taxanes, and epothilones.
- Examination of management strategies including dose adjustments and treatment delays.
Main Results:
- Vinca alkaloids: Older agents (vincristine) caused severe neuropathy; newer agents (vinflunine) show milder, distal sensory deficits.
- Taxanes: Paclitaxel and albumin-bound paclitaxel are more associated with sensory neuropathy than docetaxel.
- Epothilones: Ixabepilone generally causes mild to moderate, reversible neuropathy, unlike potential grade 3/4 neuropathy with other epothilones.
Conclusions:
- MTI-based therapies present a risk of peripheral neuropathy in breast cancer patients.
- Newer MTIs like vinflunine and ixabepilone may offer improved neurological safety profiles.
- Effective management involves careful monitoring, dose modification, and treatment delay to mitigate neurotoxicity.
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Fungal Phylum Microsporidia
Cryptococcal Meningitis
Destabilization of Microtubules
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
